Business Context and Reporting Period
This Form 8-K reports on the 2020 Annual Meeting of Stockholders held by Miragen Therapeutics, Inc. (not Viridian Therapeutics, Inc.) on May 21, 2020. The filing was submitted on May 22, 2020. The company is incorporated in Delaware and trades on the Nasdaq Stock Market under the symbol MGEN.
Key Financial Metrics
This filing is a Current Report regarding corporate governance and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Voting Results
Stockholders representing 75.2% of outstanding shares (39,921,230 of 53,077,348 shares) participated in the meeting. The following matters were approved:
- Election of Directors: All seven nominees (William S. Marshall, Thomas E. Hughes, Kevin Koch, Joseph L. Turner, Arlene M. Morris, Jeffrey S. Hatfield, and Christopher J. Bowden) were re-elected.
- Auditor Ratification: KPMG LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2020.
- Executive Compensation: Stockholders approved the compensation of named executive officers on an advisory basis.
- Voting Frequency: Stockholders indicated a preference for annual advisory votes on executive compensation.
- Reverse Stock Split Authorization: Stockholders approved amendments to the certificate of incorporation authorizing the Board of Directors to effect a reverse stock split of Common Stock at a ratio between 1-for-3 and 1-for-20, inclusive, if deemed necessary.
Guidance, Outlook, and Risks
The filing does not contain management commentary on financial guidance, future outlook, or specific risk factors. The authorization of a potential reverse stock split suggests the company may be addressing share price or liquidity concerns, though the specific ratio and timing remain at the Board's discretion.
Key Facts for Investor Verification
- Verify the company name is Miragen Therapeutics, Inc. (MGEN), as the input metadata incorrectly referenced Viridian Therapeutics.
- Confirm the status of the authorized reverse stock split (1-for-3 to 1-for-20) in subsequent filings to determine if and when it is executed.
- Review the company's most recent 10-K or 10-Q for actual financial performance metrics, as this 8-K contains no financial data.
- Note that a significant portion of shares (21,418,701) were broker non-votes on the director election and executive compensation proposals.